本帖最后由 老马 于 2012-1-13 21:20 编辑
$ V# f0 A5 ]4 [$ g- v0 n# k' E" j; |8 I( W
爱必妥和阿瓦斯丁的比较
' ?) E3 W2 K7 i: V! c, }) {
! y( P% A* i* _http://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 | x8 t9 b% t$ k2 `+ R
$ K: E# j2 n* b5 T1 {9 f3 }
) [5 m8 j% y) q( ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
; a4 W3 K, g# X# w9 e& s- L& n$ X==================================================/ O. m- B+ k6 y- u y# d
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ V9 p/ |: W" ZPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ b% W$ R1 I, |. [
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' |. ~' L9 g2 x
|